Votrient Gains Indication for Soft Tissue Sarcoma
GlaxoSmithKline announced that the FDA has approved Votrient (pazopanib) 200mg tablets for the treatment of patients with advanced soft tissue sarcoma (STS) who have received prior chemotherapy
Bone and Connective Tissue Cancer
Childhood Cancer Survivors at Risk for Cardiac Events
Childhood cancer survivors (CCSs) treated with anthracyclines and/or cardiac irradiation have a higher risk of developing symptomatic cardiac events (CEs) in the long term.
Cancer Prevention Guidelines Updated
The American Cancer Society (ACS) Nutrition and Physical Activity Guidelines were recently updated and published in the January/February issue of CA: A Cancer Journal for Clinicians.
ROR2 ID’d As Novel Biomarker of Soft-Tissue Sarcomas
ROR2 gene mutations are expressed in a subset of soft-tissue sarcomas, including leiomyosarcoma (LMS), gastrointestinal stromal tumors (GIST), and desmoid-type fibromatosis (DTF), and expression may be indicative of poor prognosis.
